Emergence of Vitiligo during Treatment with Risankizumab-Rzaa for Plaque Psoriasis: A Case Report
To our knowledge, no cases of de novo vitiligo associated with risankizumab-rzaa have been reported in the literature, and our patient may represent the first reported case. The role of IL-23 remains unclear, and our case represents the importance of further research to better elucidate IL-23's role in vitiligo.
Authors
- Jennifer M. Tran (ORCID: https://orcid.org/0000-0003-1505-8099)
- Lisa Cotter
- Kevin Thomas (ORCID: https://orcid.org/0009-0006-7175-3300)
Institutions
- University of Wisconsin–Madison (US)
- University of Wisconsin Health (US)
- Wisconsin Division of Public Health (US)
Publication Details
- Journal
- Case Reports in Dermatology
- Published
- 2025-12-20
- DOI
- https://doi.org/10.1159/000548980
- Primary Topic
- melanin and skin pigmentation
- Type
- article
- Field-Weighted Citation Impact
- 0.00